3-[5-chloro-2-(1-thiophen-2-ylimidazol-4-yl)phenyl]-1-(furan-2-yl)-4-phenyltriazol-1-ium
C25H17ClN5OS+ — CID 123414388
Data last refreshed: (MolForge compound catalog, from PubChem)
About 3-[5-chloro-2-(1-thiophen-2-ylimidazol-4-yl)phenyl]-1-(furan-2-yl)-4-phenyltriazol-1-ium
3-[5-chloro-2-(1-thiophen-2-ylimidazol-4-yl)phenyl]-1-(furan-2-yl)-4-phenyltriazol-1-ium (PubChem CID 123414388) has the molecular formula C25H17ClN5OS+ and a molecular weight of 470.97 g/mol. Its IUPAC name is 3-[5-chloro-2-(1-thiophen-2-ylimidazol-4-yl)phenyl]-1-(furan-2-yl)-4-phenyltriazol-1-ium.
Molecular Properties
| Compound Name | 3-[5-chloro-2-(1-thiophen-2-ylimidazol-4-yl)phenyl]-1-(furan-2-yl)-4-phenyltriazol-1-ium |
|---|---|
| PubChem CID | 123414388 |
| Molecular Formula | C25H17ClN5OS+ |
| Molecular Weight | 470.97 g/mol |
| Exact Mass | 470.08 |
| IUPAC Name | 3-[5-chloro-2-(1-thiophen-2-ylimidazol-4-yl)phenyl]-1-(furan-2-yl)-4-phenyltriazol-1-ium |
| SMILES | Clc1ccc(-c2cn(-c3cccs3)cn2)c(-n2n[n+](-c3ccco3)cc2-c2ccccc2)c1 |
| InChI | InChI=1S/C25H17ClN5OS/c26-19-10-11-20(21-15-29(17-27-21)25-9-5-13-33-25)22(14-19)31-23(18-6-2-1-3-7-18)16-30(28-31)24-8-4-12-32-24/h1-17H/q+1 |
| InChIKey | HYWOSTAKYVWNMQ-UHFFFAOYSA-N |
| XLogP | 5.98 |
| TPSA | 52.66 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 33 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 470.97 |
| LogP ≤ 5 | 5.98 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 6 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'quaternary_nitrogen_1', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 123414388 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.